S&P 500   4,519.63
DOW   35,457.31
QQQ   375.47
S&P 500   4,519.63
DOW   35,457.31
QQQ   375.47
S&P 500   4,519.63
DOW   35,457.31
QQQ   375.47
S&P 500   4,519.63
DOW   35,457.31
QQQ   375.47
NASDAQ:CRSP

CRISPR Therapeutics Stock Forecast, Price & News

$100.26
+4.05 (+4.21 %)
(As of 10/19/2021 04:00 PM ET)
Add
Compare
Today's Range
$97.34
$102.96
50-Day Range
$96.21
$135.39
52-Week Range
$84.38
$220.20
Volume1.92 million shs
Average Volume1.64 million shs
Market Capitalization$7.64 billion
P/E Ratio19.62
Dividend YieldN/A
Beta2.26
30 days | 90 days | 365 days | Advanced Chart
Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CRISPR Therapeutics logo

About CRISPR Therapeutics

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Employees
410
Year Founded
N/A

Sales & Book Value

Annual Sales
$720,000.00
Price / Sales
10,610.99
Book Value
$23.37 per share

Profitability

Net Income
$-348.86 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$7.64 billion
Next Earnings Date
10/27/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.42 out of 5 stars

Medical Sector

172nd out of 1,360 stocks

Biological Products, Except Diagnostic Industry

24th out of 196 stocks

Analyst Opinion: 4.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for CRISPR Therapeutics
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Thursday, July, 29th. The company reported $9.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.52 by $5.92. The company had revenue of $900.70 million for the quarter, compared to analysts' expectations of $678.05 million. CRISPR Therapeutics had a net margin of 49.52% and a trailing twelve-month return on equity of 24.08%.
View CRISPR Therapeutics' earnings history
.

How has CRISPR Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 131.7% and is now trading at $100.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRSP?

18 equities research analysts have issued 1-year target prices for CRISPR Therapeutics' stock. Their forecasts range from $101.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $158.94 in the next twelve months. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:
  • 1. SVB Leerink LLC analysts commented, " (10/19/2021)
  • 2. According to Zacks Investment Research, "CRISPR Therapeutics' lead pipeline candidate CTX001, a CRISPR gene-edited therapy, is being developed for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in collaboration with Vertex. If successfully developed, CTX001 can reap huge profits as both diseases have a high unmet medical need. The company’s other pipeline candidates are in early-stage development for various cancer indications. However, in absence of a marketed product, it is solely dependent on Vertex for collaborations revenues, which remains a constant woe. Moreover, its candidates are years away from achieving commercialization. Acute competition is also a worry for CRISPR Therapeutics as some companies are developing gene-edited therapies. Shares of the company have outperformed the industry year to date." (2/1/2021)

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Carnegie Capital Asset Management LLC (0.16%), Ipswich Investment Management Co. Inc. (0.04%), Bouvel Investment Partners LLC (0.02%), Harbor Investment Advisory LLC (0.02%), Green Alpha Advisors LLC (0.02%) and Private Advisor Group LLC (0.02%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics
.

Which institutional investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Winfield Associates Inc., Bouvel Investment Partners LLC, Harbor Investment Advisory LLC, and Wedbush Securities Inc.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CRISPR Therapeutics stock?

CRSP stock was bought by a variety of institutional investors in the last quarter, including Northstar Advisory Group LLC, Private Advisor Group LLC, City Holding Co., Green Alpha Advisors LLC, Foundations Investment Advisors LLC, Carnegie Capital Asset Management LLC, Fifth Third Bancorp, and Ipswich Investment Management Co. Inc..
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $100.26.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $7.64 billion and generates $720,000.00 in revenue each year. The company earns $-348.86 million in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.